Home  »  Industry   »  Which institution holds the most shares in NGM Bio...

Which institution holds the most shares in NGM Biopharmaceuticals Inc. (NGM)

NGM Biopharmaceuticals Inc. (NASDAQ: NGM) is -69.90% lower on its value in year-to-date trading and has touched a low of $2.92 and a high of $20.01 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NGM stock was last observed hovering at around $5.34 in the last trading session, with the day’s loss setting it -0.01%.

Currently trading at $5.33, the stock is -0.97% and -38.96% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.23 million and changing -0.19% at the moment leaves the stock -59.86% off its SMA200. NGM registered -71.77% loss for a year compared to 6-month loss of -60.69%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The stock witnessed a 13.16% gain in the last 1 month and extending the period to 3 months gives it a -66.20%, and is 0.76% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.83% over the week and 8.94% over the month.

NGM Biopharmaceuticals Inc. (NGM) has around 225 employees, a market worth around $433.97M and $58.10M in sales. Distance from 52-week low is 82.53% and -73.36% from its 52-week high.

NGM Biopharmaceuticals Inc. (NGM) Analyst Forecasts

NGM Biopharmaceuticals Inc. is expected to release its quarterly report on 03/01/2023.The EPS is expected to shrink by -4.30% this year

NGM Biopharmaceuticals Inc. (NGM) Top Institutional Holders

The shares outstanding are 80.62M, and float is at 64.61M with Short Float at 3.34%.

NGM Biopharmaceuticals Inc. (NGM) Insider Activity

A total of 54 insider transactions have happened at NGM Biopharmaceuticals Inc. (NGM) in the last six months, with sales accounting for 0 and purchases happening 54 times. The most recent transaction is an insider purchase by COLUMN GROUP L P, the company’s Director. SEC filings show that COLUMN GROUP L P bought 4,330 shares of the company’s common stock on Nov 22 at a price of $5.00 per share for a total of $21646.0. Following the purchase, the insider now owns 0.38 million shares.

NGM Biopharmaceuticals Inc. disclosed in a document filed with the SEC on Nov 22 that COLUMN GROUP L P (Director) bought a total of 4,330 shares of the company’s common stock. The trade occurred on Nov 22 and was made at $5.00 per share for $21646.0. Following the transaction, the insider now directly holds 0.38 million shares of the NGM stock.

Still, SEC filings show that on Nov 22, COLUMN GROUP L P (Director) acquired 4,330 shares at an average price of $5.00 for $21646.0. The insider now directly holds 380,172 shares of NGM Biopharmaceuticals Inc. (NGM).

NGM Biopharmaceuticals Inc. (NGM): Who are the competitors?

The company’s main competitors (and peers) include Merck & Co. Inc. (MRK) that is trading 29.01% up over the past 12 months and Madrigal Pharmaceuticals Inc. (MDGL) that is -19.46% lower over the same period. Intercept Pharmaceuticals Inc. (ICPT) is -14.24% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.